查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016039

造影劑市場報告：按類型、模式、應用、給藥途徑、最終用戶和地區分類（2026-2034 年）

Contrast Media Market Report by Type, Modality (X-ray/Computed Tomography, Magnetic Resonance Imaging, Ultrasound), Application, Route of Administration, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年全球造影劑市場規模達51億美元。 IMARC Group預測，到2034年，該市場規模將達到69億美元，2026年至2034年的複合年成長率（CAGR）為3.41%。北美市場優勢明顯，這主要得益於放射性藥物需求的不斷成長。此外，神經系統疾病、癌症和心血管疾病發生率的上升也帶動了診斷影像需求的成長，這是推動市場成長的另一個關鍵因素。

市場規模及預測：

  • 2025年，造影劑市場價值將達51億美元。
  • 預計到 2034 年，該市場規模將達到 69 億美元，2026 年至 2034 年的複合年成長率為 3.41%。

主要部分：

  • 類型：含碘造影劑含有碘原子，可用於基於 X光的成像診斷方法，如電腦斷層掃描 (CT)，使其在市場上佔據主導地位。
  • 影像方式：X光/電腦斷層掃描（CT）佔據了大部分市場佔有率，這得益於診斷影像技術的日益普及。
  • 應用領域：介入性心臟病學目前佔據最大的市場佔有率。這是由於對冠動脈攝影術和經皮冠狀動脈介入治療（PCI）等技術的需求不斷成長，這些技術嚴重依賴造影劑來顯示心臟的血管結構和功能。
  • 給藥途徑：靜脈/動脈內給藥的有效性在於它能將造影劑直接輸送到血液中，確保造影劑快速分佈到目標器官或全身，因此在造影劑市場中佔據主導地位。
  • 地區：北美市場領先，這得益於大型製藥企業的存在以及FDA等監管機構的支持。

主要企業：

  • 市場上的主要企業包括拜耳股份公司、北京北路藥業股份有限公司、布拉科集團、FUJIFILM索諾施特、通用電氣醫療集團、格爾貝、iMAX、JB製藥、Jodas Expoim、蘭特斯、賽諾赫米亞製藥、泰君製藥和特里維特龍醫療。

市場成長的主要促進因素：

  • 診斷影像的增加：隨著 MRI、CT 和 X 光檢查等診斷影像測試的增加，造影被不斷使用，以提供更清晰的影像並提高診斷能力。
  • 慢性病盛行率增加：癌症、心血管疾病和神經系統疾病等慢性病的發生率正在上升，因此需要繼續使用造影影像技術進行有效診斷和監測治療進展。
  • 技術進步：造影劑成分的不斷進步，例如開發出更安全、更有效、副作用更少的造影劑，帶來了更好的臨床效果和更廣泛的應用。
  • 醫療基礎設施的擴張：對醫療設施的持續投資，尤其是在開發中國家，使得更先進的診斷服務得以提供，這反過來又增加了對造影劑的需求。
  • 有利的報銷政策：政府和私人保險公司透過報銷計畫積極支持影像診斷程序，從而確保在常規臨床實踐中繼續使用造影劑。

未來展望：

  • 強勁的成長前景：在全球醫療保健支出不斷成長、診斷能力不斷提高以及診斷成像技術不斷進步的推動下，造影劑業務正在穩步成長。
  • 市場演變：該行業不斷發展，造影劑擴大被納入精準醫療和介入治療中，為跨臨床專科和地區的廣泛應用開闢了道路。

造影劑市場正經歷動態演變，多種趨勢共同推動其當前及未來的發展軌跡。監管機構正在加強對造影劑安全性、有效性和環境毒性的監管。製造商則透過採用永續的生產方式和強化廢棄物管理機制來提升合規性。環境中的钆殘留問題正受到更嚴格的審查，這促使可生物分解和低劑量製劑的研發。各機構正在調整營運以適應不斷變化的法律規範，從而維持市場的長期永續性。隨著醫療保健產業向門診服務轉型，影像中心和門診服務提供者正成為造影劑的主要終端使用者。這些影像中心重視基於快速起效且經濟實惠的造影劑的高通量影像服務。供應商也在調整產品線以滿足門診診所的服務需求，並專注於便利性、儲存空間和快速的患者回應。

造影劑產業的發展趨勢：

診斷影像檢查增加

電腦斷層掃描（CT）、X光、磁振造影（MRI）和超音波等診斷影像檢查在全球醫療系統中日益普及，成為常規臨床評估的一部分。診斷中心和醫院擴大使用對比增強影像技術，以更清晰地顯示內臟器官、血管和疾病進展。醫師更常使用造影來提高觀察的敏感度和特異性，從而提高診斷和治療方案製定的準確性。人口老化、慢性病發病率上升以及對預防醫學日益重視，都推動了對診斷造影需求的成長。隨著醫學影像在現代醫學中發揮越來越重要的作用，造影劑的使用量也相應增加。另一個重要因素是醫療專業人員在臨床實務中對先進診斷影像技術的應用。根據世界衛生組織（世衛組織）的數據，到2024年，全球整體出生時的平均壽命將達到73.3歲，比1995年增加8.4歲。預計到2030年，全球60歲以上人口將達14億人。這一趨勢將進一步推動對高效老年人影像診斷解決方案的需求。

慢性病和文明病的增加

全球醫療保健產業正努力應對慢性疾病和文明病（例如癌症、心血管疾病、糖尿病和神經系統併發症）所帶來的沉重負擔。醫生們擴大利用造影增強影像技術來更有效地診斷、後續觀察和治療這些疾病。例如，在腫瘤學領域，造影劑可以幫助放射科醫師更清晰地識別腫瘤邊界、轉移範圍和治療反應。在循環系統，造影劑有助於評估冠狀動脈疾病、心肌灌注和結構異常。在中風和多發性硬化症等神經系統疾病中，對比造影影像對於進行正確的評估和後續觀察也至關重要。由於老化、久坐的生活方式和環境問題等因素，這些慢性疾病的發生率日益上升，對先進影像技術的需求也隨之成長。日益加重的疾病負擔促使醫療保健機構加強對影像能力的投資，從而不斷推動全球不同地區和不同醫療保健體系中造影劑市場的發展。 2024年，布拉格細胞生物學研究所（IOCB）的研究團隊與德國圖賓根大學理學院和查理大學合作，開發出一種新型造影劑，可用於磁振造影（MRI）和正子斷層掃描（PET）。這項突破解決了先前阻礙這兩種成像技術整合到同一設備中的一大難題。

造影劑配方創新

製藥公司正積極投資研發，以開發更先進、更安全、更具標靶性的造影劑。研究人員正在開發低滲透壓和等滲碘基造影劑、大環钆造影劑以及具有更高安全性和更少副作用的可生物分解微氣泡造影劑。這些創新降低了造影腎臟病和腎源性系統性纖維化等併發症的風險，尤其是在腎功能受損的患者。研究人員也致力於開發成像精度高且能快速從體內排放的造影劑。靶向特定疾病指標的靶向和分子水平造影劑的湧現也有助於提高診斷準確性。這些進步使得更個人化和有效的影像診斷成為可能，從而改善患者預後並最佳化臨床決策。根據IMARC Group預測，到2033年，全球精準診斷市場規模預計將達到2,070億美元。

造影劑市場成長促進因素：

新興市場醫療衛生基礎建設

在新興市場，政府支出增加、私人投資和國際支持推動醫療保健產業快速變革。這些市場的診斷中心和醫院正透過投資先進的影像技術並常規應用造影增強成像來提升自身能力。各國政府也正在實施包括疾病早期篩檢在內的公共衛生項目，這些項目促進了診斷影像技術的更廣泛應用。可負擔醫療保險的普及和中產階級的壯大也推動了高品質醫療服務（包括造影增強影像）的普及。隨著醫療基礎設施的完善，對造影的需求也不斷成長。製藥公司正透過進入市場、與當地合作夥伴攜手以及提供符合當地需求的產品來滿足這一需求。

人工智慧（AI）與影像技術的融合

醫學影像診斷正日益數位化，人工智慧 (AI) 和機器學習 (ML) 技術已成為診斷實踐中不可或缺的組成部分。放射科醫生和影像中心正擴大採用人工智慧來提高影像判讀的準確性、簡化重複性工作並最佳化造影劑的使用。人工智慧演算法有助於精確量化造影劑的吸收，使臨床醫生能夠根據每位患者的特徵確定最佳造影劑劑量。這些技術還有助於早期發現異常情況、最大限度地減少人為誤差並最佳化診斷成像的整體效率。設備製造商正穩步將人工智慧功能整合到 CT、MRI 和超音波診斷設備中，從而實現即時回饋和影像參數的自動調整。這種技術整合在提高診斷性能的同時，最大限度地減少了造影劑的使用，從而兼顧了成本效益和患者安全。

對微創和影像引導介入治療的需求日益成長

由於微創介入治療具有恢復時間短、併發症少、住院時間短等優點，在大多數臨床情況下日益成為第一線治療方法。特別是介入放射學，隨著醫生進行血管造影術、栓塞、切片檢查和支架置入等影像導引手術，其發展勢頭迅猛。造影劑對於這些手術至關重要，它能夠即時顯示內部結構影像，並高精度地引導手術器械。醫院和外科中心不斷提升其在介入放射學和血管內治療方面的能力，從而導致造影劑在診斷和治療領域的應用日益廣泛。這一趨勢的驅動力源於影像技術的進步以及專為這些手術設計的造影劑的研發。隨著微創方法在越來越多的醫學專科中成為常規實踐，對造影影像的需求也日益成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球造影劑市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 碘造影劑
  • 钆基造影劑
  • 微氣泡造影劑
  • 鋇基造影劑

第7章 市場區隔：依模式分類

  • X光/電腦斷層掃描（CT）
  • 磁振造影（MRI）
  • 超音波

第8章 市場區隔：依應用領域分類

  • 放射科
  • 介入放射學
  • 介入性心臟病學

第9章 市場區隔：依給藥途徑

  • 靜脈注射/動脈注射
  • 口服
  • 直腸給藥
  • 其他

第10章 市場區隔：依最終用戶分類

  • 醫院、診所及門診手術中心
  • 診斷影像中心

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Bayer AG
    • Beijing Beilu Pharmaceuticals Company Limited
    • Bracco Group
    • FUJIFILM Sonosite, Inc.
    • GE HealthCare
    • Guerbet
    • iMAX
    • JB Pharma
    • Jodas Expoim Pvt. Ltd.
    • Lantheus
    • SANOCHEMIA Pharmazeutika GmbH
    • TAEJOON PHARM Co. Ltd.
    • Trivitron Healthcare
Product Code: SR112026A6234

The global contrast media market size reached USD 5.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 6.9 Billion by 2034, exhibiting a growth rate (CAGR) of 3.41% during 2026-2034. North America exhibits a clear dominance in the market, attributed to the escalating demand for radiopharmaceuticals. Moreover, the increasing demand for diagnostic imaging procedures, owing to the growing prevalence of neurological, cancer, and cardiovascular diseases, is one of the key factors stimulating the market growth.

MARKET SIZE & FORECASTS:

  • Contrast media market was valued at USD 5.1 Billion in 2025.
  • The market is projected to reach USD 6.9 Billion by 2034, at a CAGR of 3.41% from 2026-2034.

DOMINANT SEGMENTS:

  • Type: Iodinated contrast media exhibits a clear dominance in the market as it contains iodine atoms, which can be used for x-ray-based imaging modalities, such as computed tomography (CT).
  • Modality: X-ray/computed tomography (CT) accounts for the majority of the total market share propelled by the inflating popularity of diagnostic imaging procedures.
  • Application: Interventional cardiology currently holds the largest market share, owing to the escalating demand for techniques, such as coronary angiography and percutaneous coronary interventions (PCI), which widely rely on contrast media to visualize the heart's vascular structure and function.
  • Route of Administration: Intravenous/intrarterial route exhibits a clear dominance in the contrast media market share, owing to their effectiveness in delivering contrast agents directly into the bloodstream, thereby ensuring rapid distribution throughout the targeted organs or body.
  • Region: North America leads the market due to the presence of major pharmaceutical companies and regulatory support from bodies like the FDA.

KEY PLAYERS:

  • The leading companies in the market include Bayer AG, Beijing Beilu Pharmaceuticals Company Limited, Bracco Group, FUJIFILM Sonosite, Inc., GE HealthCare, Guerbet, iMAX, JB Pharma, Jodas Expoim Pvt. Ltd., Lantheus, SANOCHEMIA Pharmazeutika GmbH, TAEJOON PHARM Co. Ltd., Trivitron Healthcare, etc.

KEY DRIVERS OF MARKET GROWTH:

  • Increasing Diagnostic Imaging Procedures: The increase in diagnostic imaging, such as MRI, CT, and X-ray procedures, is driving the constant use of contrast agents to provide more distinct images and enhance diagnostic capabilities.
  • Increasing Prevalence of Chronic Diseases: The growing occurrence of chronic ailments like cancer, cardiovascular disease, and neurological disorders is necessitating sustained use of contrast-enhanced imaging for effective diagnosis and monitoring of treatment.
  • Technological Developments: Consecutive advancements in contrast media compositions, such as the creation of safer and more effective agents with fewer side effects, are improving clinical results and widening their scope of application.
  • Increasing Healthcare Infrastructure: Repeated investments in healthcare facilities, especially in developing countries, are making more sophisticated diagnostic services accessible, thus increasing the demand for contrast media.
  • Positive Reimbursement Policies: Governments and commercial payers are favorably supporting diagnostic imaging procedures via reimbursement programs, leading to continued use of contrast agents within regular clinical practice.

FUTURE OUTLOOK:

  • Strong Growth Outlook: Contrast media business is witnessing steady growth with favorable global healthcare expenditure, growing diagnostic capabilities, and technological improvements in imaging technologies.
  • Market Evolution: The business is ever-developing, with contrast agents becoming more and more incorporated into precision medicine and interventional care, opening the door to broader application across clinical specialties and geographies.

Contrast media market is experiencing dynamic evolution, and various trends are driving its current and future path. Regulatory organizations are making regulations stricter regarding the safety, efficacy, and environmental toxicity of contrast agents. Producers are embracing compliance by incorporating sustainable production methodologies and enhancing waste control mechanisms. Gadolinium retention in the environment issues are inviting more scrutiny, paving the way for biodegradable and reduced-dose formulations. Organizations are aligning their businesses with changing regulatory paradigms to maintain long-term market sustainability. As the healthcare sector is transitioning toward outpatient procedures, imaging centers and ambulatory service providers are emerging as principal end users of contrast media. Such imaging centers are placing emphasis on high-throughput imaging services based on fast-acting and economical contrast agents. Suppliers are also modifying their product lines to address the service requirements of outpatient clinics, focusing on convenience, storage space, and quick patient turnaround.

CONTRAST MEDIA INDUSTRY TRENDS:

Rising Use of Diagnostic Imaging Studies

The healthcare systems of the world are conducting more diagnostic imaging tests, such as computed tomography (CT) scans, X-rays, magnetic resonance imaging (MRI), and ultrasounds, as a routine part of clinical evaluation. Diagnostic centers and hospitals are increasingly using contrast-enhanced studies to obtain better visualization of internal organs, blood vessels, and disease processes. Physicians are making more use of contrast agents to enhance the sensitivity and specificity of imaging findings, thus enhancing diagnosis and treatment planning. This increased demand for imaging is based on the aging population, rise in chronic disease incidence, and greater emphasis on preventive medicine. With medical imaging increasingly becoming an important part of contemporary medicine, contrast medium consumption is growing correspondingly. Another crucial aspect is that advances in imaging technologies are also being incorporated into clinical practices by healthcare providers. As per World Health Organization (WHO), worldwide, life expectancy at birth hit 73.3 years in 2024, a rise of 8.4 years since 1995. The global population of individuals aged 60 and above is expected to reach 1.4 billion by 2030. This trend is further going to drive the need for efficient diagnostic imaging solutions for the geriatric population.

Increasing Incidence of Chronic and Lifestyle Diseases

The burden of chronic and lifestyle-related diseases, such as cancer, cardiovascular disorders, diabetes, and neurological complications is being managed by the healthcare sector of the world. Doctors are increasingly using contrast-enhanced imaging to diagnose, monitor, and treat such diseases more efficiently. In oncology, for example, contrast agents are assisting radiologists in defining tumor margins, metastatic extent, and treatment response more clearly. In cardiology, contrast media are assisting in the assessment of coronary artery diseases, cardiac perfusion, and structural disorders. Neurological illnesses like stroke and multiple sclerosis are also necessitating contrast imaging for their proper evaluation and monitoring. With these long-term illnesses becoming increasingly common due to factors like aging populations, sedentary lifestyles, and environmental issues, demand for cutting-edge diagnostic imaging is gaining traction. This increase in disease burden is encouraging healthcare providers to make investments in imaging capacities, thereby constantly facilitating the development of the contrast media market in various regions of the world and varying healthcare systems. In 2024, A research group from IOCB Prague, in partnership with the University of Tubingen in Germany and the Faculty of Science at Charles University, created a novel type of contrast agent suitable for use in both magnetic resonance imaging (MRI) and positron emission tomography (PET). This advancement addressed a significant challenge that had formerly obstructed the combination of these two imaging methods into one device.

Innovation in Contrast Agent Formulations

Pharma companies are proactively investing in research and development (R&D) to develop more sophisticated, safer, and targeted contrast media formulations. Researchers are creating low-osmolar and iso-osmolar iodine-based agents, macrocyclic gadolinium-based agents, and biodegradable microbubble agents with better safety profiles and fewer adverse effects. These innovations are reducing the risk of complications like contrast-induced nephropathy and nephrogenic systemic fibrosis, particularly in patients with impaired renal function. Researchers are also designing agents with greater imaging accuracy and quicker clearance from the body. The growth of targeted and molecular contrast agents for particular disease indicators is also enhancing diagnostic precision. These progressive developments are allowing better personalized and effective imaging, improving patient outcomes and clinical decision-making. IMARC Group predicts that the global precision diagnostics market is projected to attain USD 207.0 Billion by 2033.

CONTRAST MEDIA MARKET GROWTH DRIVERS:

Development of Healthcare Infrastructure in Emerging Markets

The emerging markets are witnessing fast-paced healthcare change through rising government expenditure, private investment, and global aid. Diagnostic centers and hospitals in these markets are increasing their capabilities by making investments in advanced imaging technology and adding contrast-enhanced procedures to everyday use. Governments are also introducing public health programs that include early disease detection, which is stimulating broader applications of diagnostic imaging. Improved access to affordable health insurance and expanding middle classes are also facilitating access to quality healthcare services, such as contrast-based diagnostics. With the growth of healthcare infrastructure, demand for contrast media is rising. Pharmaceutical firms are countering by entering the markets, establishing local alliances, and offering products aligned to local needs.

Artificial Intelligence (AI) and Imaging Technology integration

Medical imaging is undergoing digitalization, with artificial intelligence (AI) and machine learning (ML) technologies increasingly forming an integral part of diagnostic practice. Radiologists and imaging facilities are increasingly adopting AI to improve image interpretation, streamline repetitive tasks, and maximize contrast agent usage. AI algorithms are assisting with accurate quantification of contrast uptake, enabling clinicians to determine optimal contrast dosage according to patient-specific features. These devices are also enhancing early abnormal detection, minimizing human mistake, and optimizing overall imaging efficiency. Machine manufacturers are steadily incorporating AI functionality into CT, MRI, and ultrasound machines, allowing real-time feedback and automatic adjustment of image parameters. This technology convergence is enhancing diagnostic performance while minimizing contrast agent volume, supporting both cost-effectiveness and patient safety.

Growing Demand for Minimally Invasive and Image-Guided Interventions

Minimally invasive interventions are increasingly becoming the treatment method of choice in a vast majority of clinical situations because they have shorter recovery times, fewer complications, and fewer hospital stays. Interventional radiology, specifically, is picking up pace as doctors carry out image-guided procedures like angiography, embolization, biopsy, and stent placement. Such procedures depend significantly on contrast media to obtain real-time imaging of internal structure and to direct instruments with high accuracy. Hospitals and surgical centers are constantly increasing their capabilities in interventional radiology and endovascular therapies, raising the use of contrast agents in both diagnostic and therapeutic applications. This trend is driven by technological advances in imaging technologies and procedure-specific contrast preparations. As minimally invasive methods become routine practice in ever more medical specialties, the need for contrast-enhanced imaging is increasing.

CONTRAST MEDIA MARKET SEGMENTATION:

Breakup by Type:

  • Iodinated Contrast Media
  • Gadolinium-based Contrast Media
  • Microbubble Contrast Media
  • Barium-based Contrast Media

Among these, iodinated contrast media currently exhibits a clear dominance in the market

Iodinated contrast media refer to contrast agents that contain iodine atoms used for x-ray-based imaging modalities, such as computed tomography (CT). Moreover, they can also be used in angiography, venography, fluoroscopy, and even occasionally, plain radiography. Besides this, key players are launching iodinated contrast media agents, as they enhance the diagnostic capabilities of CT and other radiographic imaging techniques. For example, in July 2022, Fresenius Kabi introduced the generic iodinated contrast media agent to alleviate the shortage. In addition to this, in October 2022, GE Healthcare entered into a long-term agreement with Chile-based mining company Sociedad Quimica y Minera de Chile S.A. (SQM) to secure its supply of iodine, a key ingredient for contrast media products used in computed tomography (CT) procedures globally.

Breakup by Modality:

  • X-ray/Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Ultrasound

Currently, X-ray/computed tomography (CT) accounts for the majority of the total market share

The growth in this segmentation is propelled by the inflating popularity of diagnostic imaging procedures. Additionally, these imaging techniques are fundamental in medical diagnostics due to their ability to provide quick, detailed views of the body's internal structures, thereby making them crucial for the early diagnosis, detection, and management of diseases. Besides this, various technological advancements in X-ray and CT imaging technologies to expand their application in clinical practice are elevating the contrast media market prices. For instance, in September 2023, Smiths Detection developed its HI-SCAN 6040 CTiX, an advanced cabin baggage screening system based on computed tomography (CT) technology, for the market across India. Similarly, in November 2023, Annalise.ai introduced the Annalise Triage software platform for chest X-rays and non-contrast head CT.

Breakup by Application:

  • Radiology
  • Interventional Radiology
  • Interventional Cardiology

Among these, interventional cardiology currently holds the largest market share

The escalating demand for techniques, such as coronary angiography and percutaneous coronary interventions (PCI), which widely rely on contrast media to visualize the heart's vascular structure and function, is stimulating the segment's growth. Furthermore, the increasing prevalence of cardiovascular diseases, coupled with advancements in cardiac imaging technologies, are increasing the number of these procedures. Apart from this, the launch of medical programs related to interventional cardiology will continue to bolster the market in the coming years. For example, in May 2024, the Society for Cardiovascular Angiography & Interventions (SCAI) started its SCAI scientific sessions in Long Beach, California, bringing together more than 1,800 researchers, clinicians, and innovators in the field of interventional cardiology and endovascular medicine.

Breakup by Route of Administration:

  • Intravenous/Intrarterial
  • Oral Route
  • Rectal Route
  • Others

Currently, intravenous/intrarterial route exhibits a clear dominance in the contrast media market share

The intravenous and intraarterial routes of administration find widespread applications, owing to their effectiveness in delivering contrast agents directly into the bloodstream, thereby ensuring rapid distribution throughout the targeted organs or body. This method is pivotal for enhancing the clarity of images in several diagnostic imaging procedures, including MRI, CT scans, and angiography. The intravenous route is particularly prevalent because it can be used for a wide range of imaging studies that require a systemic distribution of the contrast agent and is relatively easy to administer. For instance, in May 2023, Guerbet, one of the global leaders in medical imaging, announced that based on the scientific and clinical evidence, the ACR Committee on Drugs and Contrast Media classified elucirem as a Group II agent. 6 and indicated for use in adults and children aged two years and older. On the other hand, the intraarterial route offers a more targeted approach. It is used in procedures, including coronary angiograms, where the contrast media is injected directly into the arteries of the heart to obtain detailed images of the coronary circulation.

Breakup by End User:

  • Hospital, Clinics and Ambulatory Surgery Centers
  • Diagnostic Imaging Centers

According to the contrast media market research report, the availability of advanced imaging equipment across hospitals is acting as a significant growth-inducing factor. In addition to this, clinics, particularly those specializing in specific fields like cardiology or oncology, use contrast media for targeted diagnostic purposes. Moreover, ambulatory surgery centers extensively adopt imaging technologies that require contrast media, particularly for preoperative and postoperative assessments. Besides this, diagnostic imaging centers cater to both referrals from hospitals and smaller clinics.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The expanding healthcare infrastructures and a high rate of medical imaging procedures are driving the regional market. For example, in April 2024, the Northwest Imaging Forums (NWIF) and International Contrast Ultrasound Society (ICUS) announced an educational partnership to aid in training sonographers to perform contrast-enhanced ultrasound (CEUS) examinations and administer intravenous ultrasound contrast agents. Besides this, the presence of major pharmaceutical companies is also acting as another significant growth-inducing factor. For instance, in September 2023, Philips introduced the microvascular imaging super resolution contrast-enhanced ultrasound (CEUS), which was showcased at the International Bubble Conference in Chicago. Furthermore, regulatory support from bodies like the FDA also plays a crucial role in the swift approval and adoption of new contrast agents, which is expected to fuel the regional market in the coming years. For example, in August 2023, Fresenius Kabi, a German healthcare company with headquarters in Illinois, launched an FDA-approved generic substitute for Gadavist, the gadolinium-based contrast agent commonly used during MRI exams.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Bayer AG
  • Beijing Beilu Pharmaceuticals Company Limited
  • Bracco Group
  • FUJIFILM Sonosite, Inc.
  • GE HealthCare
  • Guerbet
  • iMAX
  • JB Pharma
  • Jodas Expoim Pvt. Ltd.
  • Lantheus
  • SANOCHEMIA Pharmazeutika GmbH
  • TAEJOON PHARM Co. Ltd.
  • Trivitron Healthcare

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global contrast media market in 2025?

2. What is the expected growth rate of the global contrast media market during 2026-2034?

3. What has been the impact of COVID-19 on the global contrast media market?

4. What are the key factors driving the global contrast media market?

5. What is the breakup of the global contrast media market based on the type?

6. What is the breakup of the global contrast media market based on the modality?

7. What is the breakup of the global contrast media market based on the application?

8. What is the breakup of the global contrast media market based on the route of administration?

9. What are the key regions in the global contrast media market?

10. Who are the key players/companies in the global contrast media market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Contrast Media Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Iodinated Contrast Media
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Gadolinium-based Contrast Media
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Microbubble Contrast Media
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Barium-based Contrast Media
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Modality

  • 7.1 X-ray/Computed Tomography (CT)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Magnetic Resonance Imaging (MRI)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Ultrasound
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Radiology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Interventional Radiology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Interventional Cardiology
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Intravenous/Intrarterial
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral Route
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Rectal Route
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospital, Clinics and Ambulatory Surgery Centers
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Diagnostic Imaging Centers
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Bayer AG
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Beijing Beilu Pharmaceuticals Company Limited
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Bracco Group
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 SWOT Analysis
    • 16.3.4 FUJIFILM Sonosite, Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 GE HealthCare
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Guerbet
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 iMAX
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 JB Pharma
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
    • 16.3.9 Jodas Expoim Pvt. Ltd.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
    • 16.3.10 Lantheus
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
    • 16.3.11 SANOCHEMIA Pharmazeutika GmbH
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
    • 16.3.12 TAEJOON PHARM Co. Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
    • 16.3.13 Trivitron Healthcare
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio

List of Figures

  • Figure 1: Global: Contrast Media Market: Major Drivers and Challenges
  • Figure 2: Global: Contrast Media Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Contrast Media Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Contrast Media Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Contrast Media Market: Breakup by Modality (in %), 2025
  • Figure 6: Global: Contrast Media Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Contrast Media Market: Breakup by Route of Administration (in %), 2025
  • Figure 8: Global: Contrast Media Market: Breakup by End User (in %), 2025
  • Figure 9: Global: Contrast Media Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Contrast Media (Iodinated Contrast Media) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Contrast Media (Iodinated Contrast Media) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Contrast Media (Gadolinium-based Contrast Media) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Contrast Media (Gadolinium-based Contrast Media) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Contrast Media (Microbubble Contrast Media) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Contrast Media (Microbubble Contrast Media) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Contrast Media (Barium-based Contrast Media) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Contrast Media (Barium-based Contrast Media) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Contrast Media (X-ray/Computed Tomography (CT)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Contrast Media (X-ray/Computed Tomography (CT)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Contrast Media (Magnetic Resonance Imaging (MRI)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Contrast Media (Magnetic Resonance Imaging (MRI)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Contrast Media (Ultrasound) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Contrast Media (Ultrasound) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Contrast Media (Radiology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Contrast Media (Radiology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Contrast Media (Interventional Radiology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Contrast Media (Interventional Radiology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Contrast Media (Interventional Cardiology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Contrast Media (Interventional Cardiology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Contrast Media (Intravenous/Intrarterial) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Contrast Media (Intravenous/Intrarterial) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Contrast Media (Oral Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Contrast Media (Oral Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Contrast Media (Rectal Route) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Contrast Media (Rectal Route) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Contrast Media (Other Routes of Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Contrast Media (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Contrast Media (Hospital, Clinics and Ambulatory Surgery Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Contrast Media (Hospital, Clinics and Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Contrast Media (Diagnostic Imaging Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Contrast Media (Diagnostic Imaging Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: North America: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: North America: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: United States: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: United States: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Canada: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Canada: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Asia-Pacific: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Asia-Pacific: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: China: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: China: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Japan: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Japan: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: India: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: India: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: South Korea: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: South Korea: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Australia: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Australia: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Indonesia: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Indonesia: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Others: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Others: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Europe: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Europe: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Germany: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Germany: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: France: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: France: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: United Kingdom: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: United Kingdom: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Italy: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Italy: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Spain: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Spain: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Russia: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Russia: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Latin America: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Latin America: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Brazil: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Brazil: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Mexico: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Mexico: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Others: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Others: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Middle East and Africa: Contrast Media Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Middle East and Africa: Contrast Media Market: Breakup by Country (in %), 2025
  • Figure 90: Middle East and Africa: Contrast Media Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Global: Contrast Media Industry: SWOT Analysis
  • Figure 92: Global: Contrast Media Industry: Value Chain Analysis
  • Figure 93: Global: Contrast Media Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Contrast Media Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Contrast Media Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Contrast Media Market Forecast: Breakup by Modality (in Million USD), 2026-2034
  • Table 4: Global: Contrast Media Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Contrast Media Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 6: Global: Contrast Media Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 7: Global: Contrast Media Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Contrast Media Market: Competitive Structure
  • Table 9: Global: Contrast Media Market: Key Players